rheumatology
Medicopolitical

First biosimilar set to enter US market

After many years of debate the US are one step closer to approving the use of biosimilars. On 7 January, an FDA advisory panel unanimously voted that a drug made by Sandoz, the generics arm of Swiss pharmaceutical giant Novartis, should be accepted as a replacement for filgrastim (Neupogen) a drug used to boost the immune ...

Already a member?

Login to keep reading.


OR
© 2021 the limbic